EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Mushroom Sources: 6

Chaga Inonotus obliquus (Fr.) Pilát

Also called: cinder conk, birch conk, clinker polypore

Chaga, Inonotus obliquus, is a fungus that grows on birch trees in cold climates. The part used is a hard conk made of fungal mycelium and birch wood, usually taken as tea or powder. Its safety and efficacy have not been tested in clinical studies.

Category
Mushroom
Forms
Conk (mycelium mixed with host-tree wood), as tea, powder or extract
Strongest evidence
D Lab or animal only
Reviewed
2026-10-28

Class 4 Animal studies only. MSK states that chaga's safety and efficacy have yet to be evaluated in clinical studies; its evidence comes from cell studies and animal studies (e.g., melanoma and colitis models in mice). A PubMed search on 2026-10-30 found no human trial of chaga alone. [1]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied3 body areas · strongest grade D

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Chaga does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Chaga, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Cancer cells and tumors in the laboratoryDExtracts and constituents such as inotodiol inhibited colon, lung, liver and cervical cancer cells in vitro and melanoma in mice; no human studies have tested this. [1]
Blood sugarDTerpenoids inhibited the enzyme alpha-glucosidase in laboratory tests, and antidiabetic effects were studied in diabetic mice; not studied in people. [1]
Inflammation and painDAnti-inflammatory effects were seen in colitis models in mice, and pain-relieving effects in cell and animal studies; not studied in people. [1]

Main constituents: Oxalic, gallic, protocatechuic and p-hydroxybenzoic acids; inotodiol and other triterpenoids; ergosterol; polysaccharides [1]

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    2 listed

    Anticoagulant and antiplatelet drugs (e.g. warfarin); Hypoglycemic agents

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    1 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • Oxalate nephropathy (kidney damage from oxalate crystals): a 72-year-old Japanese woman who took 4–5 teaspoons of chaga powder daily for 6 months needed hemodialysis, and her kidney function did not recover. [2]
  • A 49-year-old Korean man developed end-stage kidney disease after years of chaga powder for atopic dermatitis; his remaining powder contained 14.2 g oxalate per 100 g. [3]
  • A 69-year-old man taking 10–15 g/day of chaga powder plus 500 mg/day vitamin C for 3 months developed acute kidney injury; kidney function recovered after hemodialysis and high-dose steroids. [4]
  • These harms are known from case reports; how often they occur is unknown, because chaga's safety has not been evaluated in clinical studies. [1]
Interactions

Interactions

Chaga
From the table below 2 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Chaga
WithWhat happens
Anticoagulants and antiplatelet drugsChaga extract inhibited platelet aggregation in mice and may add to these drugs' effects; clinical relevance is not known. [1]
Diabetes medicationsIn vitro, chaga had additive blood-sugar-lowering effects; clinical significance is unknown. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Natural reserves of chaga have nearly been exhausted, and cultivated substitutes for wild chaga are being developed. [1]
  • Index Fungorum lists Inonotus obliquus (Fr.) Pilát as the current name. [5]
Regulation

Regulatory status

  • US: medicinal mushrooms are sold as dietary supplements, which do not require FDA premarket evaluation and approval. The FDA has not approved medicinal mushrooms as a treatment for cancer or any other medical condition. [6]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Polysaccharides Polysaccharides [P5]
  • Inotodiol Triterpenoid [P5]
  • Oxalic, gallic, protocatechuic and p-hydroxybenzoic acids (identified in chaga extracts) Organic acid (oxalic) and phenolic acids [P5]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 1 entry naming chaga (NDI 1427 submitted 2025-07-29). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC evaluation of chaga (Inonotus obliquus) was found (IARC Monographs list of classifications checked 2026-10-29). [P3]
  • No NTP technical report on chaga (Inonotus obliquus) was found (NTP technical reports list checked 2026-10-29). [P4]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Anticoagulant and antiplatelet drugs (e.g. warfarin): MSK: chaga may have synergistic effects when used with anticoagulant/antiplatelet drugs, but clinical relevance is not known; MSK advises people taking blood thinners such as warfarin to talk with their healthcare provider because chaga may increase the risk of bleeding. [P5]
  • Hypoglycemic agents: MSK: in vitro, chaga had additive effects in lowering blood sugar levels; clinical significance is yet unknown. [P5]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of the dietary ingredient — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants a petition for an exemption under 111.75(a)(1)(ii). [P2]
  • Oxalate content — Kikuchi et al. (2014) reported a case of oxalate nephropathy after 6 months of chaga powder ingestion and state that chaga mushrooms contain extremely high oxalate concentrations. [P6]

Supply and conservation

  • IUCN Red List: Least Concern (LC), via GBIF species API, retrieved 2026-10-29 (Inonotus obliquus). [P7]
  • MSK: chaga is commonly found on birch trees in cold climates; because natural reserves of this fungus have nearly been exhausted, scientists are seeking to develop cultivated substitutes of wild chaga. The medicinal conk comprises wood from the substrate tree and mycelium of the fungus. [P5]

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  3. IARC Monographs. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  4. National Toxicology Program. Technical Reports (list checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  5. Memorial Sloan Kettering Cancer Center. About Herbs: Chaga Mushroom (last updated February 20, 2023), 2023-02-20. mskcc.org
  6. Kikuchi Y, et al. Chaga mushroom-induced oxalate nephropathy. Clin Nephrol 2014;81(6):440-4 (PMID 23149251), 2014-06. pubmed.ncbi.nlm.nih.gov
  7. GBIF species API: IUCN Red List category for Inonotus obliquus (Fr.) Pilát, 2026-10-29. api.gbif.org
Sources

Sources

  1. Memorial Sloan Kettering Cancer Center. About Herbs: Chaga Mushroom (last updated February 20, 2023), 2023-02-20. mskcc.org
  2. Kikuchi Y, et al. Chaga mushroom-induced oxalate nephropathy. Clin Nephrol 2014;81(6):440-4, 2014-06. pubmed.ncbi.nlm.nih.gov
  3. Lee S, et al. Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. J Korean Med Sci 2020;35(19):e122, 2020-05-18. pubmed.ncbi.nlm.nih.gov
  4. Kwon O, et al. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: a case report. Medicine (Baltimore) 2022;101(10):e28997, 2022-03-11. pubmed.ncbi.nlm.nih.gov
  5. Index Fungorum. Inonotus obliquus (Fr.) Pilát, record 315905 (accessed October 28, 2026). indexfungorum.org
  6. National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version (latest update 11/06/2024), 2024-11-06. cancer.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in mushroom: Cordyceps · Lion's mane · Maitake · Reishi · Shiitake · Turkey tail · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.